The results of a Phase 2 randomized clinical trial named TBCRC041, which evaluated the efficacy of Alisertib (an Aurora A kinase inhibitor) alone or in combination with Fulvestrant (an estrogen receptor antagonist) in patients with endocrine-resistant advanced breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.